Drug profile · INN
tisotumab vedotin
TIVDAK
tisotumab vedotin (TIVDAK) is a tubulin inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01FX23
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — tisotumab vedotin
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
tisotumab vedotin (TIVDAK) is a tubulin inhibitor.
Key facts
INN tisotumab vedotin
Brand TIVDAK
Mechanism Tubulin inhibitor
Target Tissue factor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX23
Mechanism of action
Tubulin inhibitor
Primary target: Tissue factor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tisotumab vedotin?
tisotumab vedotin (TIVDAK) is a tubulin inhibitor.
What is the brand name for tisotumab vedotin?
TIVDAK is a marketed brand name for tisotumab vedotin. Check FDA Drugs@FDA for the current US label holder and prescribing information.